Galectin Therapeutics Inc GALT
We take great care to ensure that the data presented and summarized in this overview for GALECTIN THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GALT
View all-
Vanguard Group Inc Valley Forge, PA2.25MShares$12.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$8.6 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$6.74 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA633KShares$3.48 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0554KShares$3.05 Million0.0% of portfolio
-
Wealthspire Advisors, LLC New York, NY480KShares$2.64 Million0.01% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA447KShares$2.46 Million0.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC360KShares$1.98 Million0.0% of portfolio
-
Geneos Wealth Management Inc.360KShares$1.98 Million0.04% of portfolio
-
Commonwealth Equity Services, LLC295KShares$1.62 Million0.0% of portfolio
Latest Institutional Activity in GALT
Top Purchases
Top Sells
About GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Insider Transactions at GALT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Harold H. Shlevin |
SELL
Open market or private sale
|
Direct |
16,790
-59.97%
|
$100,740
$6.27 P/Share
|
|
Dec 09
2025
|
Harold H. Shlevin |
BUY
Exercise of conversion of derivative security
|
Direct |
16,790
+37.49%
|
$67,160
$4.16 P/Share
|
|
Dec 08
2025
|
Harold H. Shlevin |
SELL
Open market or private sale
|
Direct |
159,000
-62.73%
|
$795,000
$5.98 P/Share
|
|
Dec 08
2025
|
Harold H. Shlevin |
BUY
Exercise of conversion of derivative security
|
Direct |
155,000
+40.7%
|
$155,000
$1.98 P/Share
|
|
Dec 03
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
120,000
-2.07%
|
$600,000
$5.73 P/Share
|
|
Dec 02
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,000
-0.51%
|
$150,000
$5.47 P/Share
|
|
Nov 18
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
46,310
-74.6%
|
$277,860
$6.22 P/Share
|
|
Nov 18
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,310
+42.69%
|
$46,310
$1.55 P/Share
|
|
Nov 18
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
6,783
-0.81%
|
$40,698
$6.15 P/Share
|
|
Nov 18
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,783
+0.8%
|
$13,566
$2.39 P/Share
|
|
Nov 17
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
31,610
-50.41%
|
$189,660
$6.03 P/Share
|
|
Nov 17
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,610
+32.21%
|
$31,610
$1.44 P/Share
|
|
Nov 17
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
15,680
-1.85%
|
$94,080
$6.04 P/Share
|
|
Nov 17
2025
|
Joel Lewis President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,680
+1.81%
|
$31,360
$2.39 P/Share
|
|
Nov 13
2025
|
Khurram Jamil Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
121,117
-85.48%
|
$605,585
$5.47 P/Share
|
|
Nov 13
2025
|
Khurram Jamil Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
99,250
+46.27%
|
$99,250
$1.98 P/Share
|
|
Nov 11
2025
|
10 X Fund, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
40,000
-0.68%
|
$200,000
$5.25 P/Share
|
|
Nov 10
2025
|
Jack W Callicutt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,291
-18.8%
|
$31,746
$6.03 P/Share
|
|
Nov 10
2025
|
Jack W Callicutt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,291
+15.73%
|
$5,291
$1.44 P/Share
|
|
Nov 10
2025
|
Joel Lewis President and CEO |
SELL
Open market or private sale
|
Direct |
1,867
-0.22%
|
$11,202
$6.03 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 909K shares |
|---|---|
| Open market or private purchase | 46K shares |
| Grant, award, or other acquisition | 32.5K shares |
| Other acquisition or disposition | 1K shares |
| Grant, award, or other acquisition | 56.4K shares |
|---|---|
| Open market or private sale | 826K shares |
| Bona fide gift | 20K shares |